Vibegron clinical trials
Also written MK-4618, RVT-901 and Gemtesa.
How each study uses vibegron is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the vibegron studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 23 Dec 2020 · GEMTESA · NDA 213006 (FDA, Drugs@FDA)
- European Union
- 27 Jun 2024 · Obgemsa · EMEA/H/C/005957 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2018 | 3 |
| 2019 | 2 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 4
Urovant Sciences GmbH (6) · Merck Sharp & Dohme LLC (4) · University of Missouri-Columbia (2) · Wake Forest University Health Sciences (1) · University of Alabama at Birmingham (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test vibegron.
- Dec 2026Impact of Early Aging and Menopause on the Vascular Responses to HypoxiaEarly Phase 1 · University of Missouri-Columbia
Studies
Open first, then newest update. How each study uses vibegron is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- Vibegron for ENergy Thinking and Resilience in AgingRecruitingPhase 3Wake Forest University Health SciencesNCT06987383Written as VibegronHow we know
- Impact of Early Aging and Menopause on the Vascular Responses to HypoxiaRecruitingEarly Phase 1University of Missouri-ColumbiaNCT06417177Written as GemtesaHow we know
- Beta3-adrenergic Receptors and Cardiovascular Function in Aging WomenRecruitingEarly Phase 1University of Missouri-ColumbiaNCT07674680Written as GemtesaHow we know
- Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CICRecruitingPhase 2/3Urovant Sciences GmbHNCT05491525Written as VibegronHow we know
- Role of Combination Therapy in Women With Refractory Overactive BladderWithdrawnNot applicableUniversity of Alabama at BirminghamNCT06438861Written as Vibegron 75mgHow we know
- Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic HyperplasiaCompletedPhase 3Urovant Sciences GmbHNCT04103450Written as VibegronHow we know
- Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)CompletedPhase 3Urovant Sciences GmbHNCT03902080Written as VibegronHow we know
- Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel SyndromeCompletedPhase 2Urovant Sciences GmbHNCT03806127Written as VibegronHow we know
- An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).CompletedPhase 3Urovant Sciences GmbHNCT03583372Written as VibegronHow we know
- A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)CompletedPhase 3Urovant Sciences GmbHNCT03492281Written as vibegronHow we know
- A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)CompletedPhase 2Merck Sharp & Dohme LLCNCT01314872Written as VibegronHow we know
- A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013)CompletedPhase 1Merck Sharp & Dohme LLCNCT01737684Written as VibegronHow we know
- A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014)CompletedPhase 1Merck Sharp & Dohme LLCNCT01628042Written as Vibegron 100 mgHow we know
- A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)TerminatedPhase 1Merck Sharp & Dohme LLCNCT01500382Written as VibegronHow we know
Given beside what is tested · 1 — vibegron is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 20, 2026.
Started recruiting1
- Vibegron for ENergy Thinking and Resilience in AgingOct 28, 2026NCT06987383
Codes
What other systems call vibegron · ClinicalTrials.gg INT000476
- UNII (FDA) M5TSE03W5UVIBEGRONConfirmed FDA, Wikidata
- RxNorm 2472254One source FDA
- Wikidata Q27283524vibegronConfirmed FDA, Wikidata
- NCI Thesaurus C152872VibegronOne source FDA
- DrugBank DB14895One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | M5TSE03W5U | VIBEGRON | Confirmed FDA, Wikidata |
| RxNorm | 2472254 | — | One source FDA |
| Wikidata | Q27283524 | vibegron | Confirmed FDA, Wikidata |
| NCI Thesaurus | C152872 | Vibegron | One source FDA |
| DrugBank | DB14895 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.